Bicara Therapeutics (BCAX) Return on Capital Employed (2024 - 2026)

Bicara Therapeutics' Return on Capital Employed history runs 3 years deep, the most recent figure standing at 38.43% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 1552.0% year-over-year to 38.43% in Q1 2026; TTM through Mar 2026 was 38.43%, a 1552.0% decrease from a year earlier, with the FY2025 full-year figure at 35.24%, down 1197.0% from the prior year.
• Return on Capital Employed rose to 38.43% in Q1 2026 per BCAX's latest filing, from 39.01% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 16.51% in Q4 2024 and bottomed at 39.01% in Q4 2025.
• The 3-year median for Return on Capital Employed is 30.37% (2025), against an average of 29.6%.
• Across the five-year window, Return on Capital Employed tumbled 2250 bps in 2025 and slumped 1552 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 16.51% in 2024, then plunged by 136 bps to 39.01% in 2025, then rose by 1 bps to 38.43% in 2026.
• Per Business Quant, the three latest BCAX Return on Capital Employed figures stand at 38.43% (Q1 2026), 39.01% (Q4 2025), and 33.75% (Q3 2025).